CD274 and neoplasm: Although one out of six mice in anti-PD-L1 monotherapy reached CR, four mice in the group receiving combination therapy of anti-TNFR2 with anti-PD-L1 reached CR, and the tumor growth was significantly suppressed (Figure 6A).